Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE): a retrospective, multicenter case series
Introduction - Metastatic renal cell carcinoma (mRCC) has a poor prognosis despite recent changes in systemic treatment options. Lenvatinib plus everolimus (LEN+EVE), a combination of 2 targeted therapies, is approved after failure of one prior tyrosine kinase inhibitor (TKI) therapy. Our objective...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2025
|
| In: |
Clinical genitourinary cancer
Year: 2025, Jahrgang: 23, Heft: 6, Pages: 1-11 |
| ISSN: | 1938-0682 |
| DOI: | 10.1016/j.clgc.2025.102449 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clgc.2025.102449 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1558767325001491 
|
| Verfasserangaben: | Hendrik Eggers, Ramona Stelmacher, Martin Bögemann, Arne Strauß, Christian Thomas, Johannes Landmesser, Stefanie Zschäbitz, Philipp Ivanyi |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1963138449 | ||
| 003 | DE-627 | ||
| 005 | 20260227121919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260227s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2025.102449 |2 doi | |
| 035 | |a (DE-627)1963138449 | ||
| 035 | |a (DE-599)KXP1963138449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Eggers, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1035126982 |0 (DE-627)746868707 |0 (DE-576)382776593 |4 aut | |
| 245 | 1 | 0 | |a Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE) |b a retrospective, multicenter case series |c Hendrik Eggers, Ramona Stelmacher, Martin Bögemann, Arne Strauß, Christian Thomas, Johannes Landmesser, Stefanie Zschäbitz, Philipp Ivanyi |
| 264 | 1 | |c December 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 6. Oktober 2025, Artikelversion: 22. November 2025 | ||
| 500 | |a Gesehen am 27.02.2026 | ||
| 520 | |a Introduction - Metastatic renal cell carcinoma (mRCC) has a poor prognosis despite recent changes in systemic treatment options. Lenvatinib plus everolimus (LEN+EVE), a combination of 2 targeted therapies, is approved after failure of one prior tyrosine kinase inhibitor (TKI) therapy. Our objective was to evaluate the effectiveness and safety of LEN+EVE therapy in patients with mRCC in a real-world setting. - Patients and Methods - This retrospective case series included patients with mRCC treatment with LEN+EVE between August 2016 and December 2021 at 6 academic centers in Germany. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety; all evaluated by local investigator. Subgroup analyses by risk scores, previous therapies, and initial dosing were performed. - Results - Eighty-one patients were assessed: median age was 61 years (range 42-80), 81.5% were men, and 80.2% of patients had an ECOG score of 0 or 1. Synchronous metastases were found in 39.5% of patients at initial diagnosis. The International Metastatic RCC Database Consortium (IMDC) risk status was favorable in 16.0%, intermediate in 48.1%, and poor in 16.0% of patients. The median number of treatment lines prior to LEN+EVE was 3 (range 0-7). Median treatment duration with LEN+EVE was 6.1 months (range 0.2-29.2). The ORR was 28.4%, DCR was 61.7%, median OS was 11.3 months (95% CI, 8.7-13.9), and median PFS was 6.5 months (95% CI, 5.4-7.6). Median PFS, OS and ORR were similar across patients with 0-2 versus ≥ 3 previous therapeutic lines and for patients with or without previous immunotherapy. The safety profile was manageable, with 6.2% of patients discontinuing treatment due to treatment-related adverse events. - Conclusions - LEN+EVE combination therapy demonstrated high effectiveness in heavily pre-treated, real-world cohort of patients with mRCC and challenging disease characteristics—regardless of treatment line, IMDC risk group, initial dosing, or previous treatment with immunotherapy. | ||
| 650 | 4 | |a Everolimus | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a Lenvatinib | |
| 650 | 4 | |a mRCC | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 700 | 1 | |a Stelmacher, Ramona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bögemann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Strauß, Arne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Landmesser, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zschäbitz, Stefanie |d 1983- |e VerfasserIn |0 (DE-588)1037698827 |0 (DE-627)75589894X |0 (DE-576)391727206 |4 aut | |
| 700 | 1 | |a Ivanyi, Philipp |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d Dallas, Tex. : CIG Media Group, 2005 |g 23(2025), 6 vom: Dez., Artikel-ID 102449, Seite 1-11 |h Online-Ressource |w (DE-627)585792658 |w (DE-600)2466266-5 |w (DE-576)358411122 |x 1938-0682 |7 nnas |a Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE) a retrospective, multicenter case series |
| 773 | 1 | 8 | |g volume:23 |g year:2025 |g number:6 |g month:12 |g elocationid:102449 |g pages:1-11 |g extent:11 |a Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE) a retrospective, multicenter case series |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clgc.2025.102449 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1558767325001491 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20260227 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1037698827 |a Zschäbitz, Stefanie |m 1037698827:Zschäbitz, Stefanie |d 910000 |d 910100 |d 50000 |e 910000PZ1037698827 |e 910100PZ1037698827 |e 50000PZ1037698827 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN1963138449 |e 4923429070 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Hendrik Eggers, Ramona Stelmacher, Martin Bögemann, Arne Strauß, Christian Thomas, Johannes Landmesser, Stefanie Zschäbitz, Philipp Ivanyi"]},"physDesc":[{"noteIll":"Illustrationen","extent":"11 S."}],"person":[{"role":"aut","given":"Hendrik","family":"Eggers","display":"Eggers, Hendrik"},{"role":"aut","display":"Stelmacher, Ramona","family":"Stelmacher","given":"Ramona"},{"role":"aut","family":"Bögemann","display":"Bögemann, Martin","given":"Martin"},{"display":"Strauß, Arne","family":"Strauß","given":"Arne","role":"aut"},{"role":"aut","given":"Christian","family":"Thomas","display":"Thomas, Christian"},{"given":"Johannes","display":"Landmesser, Johannes","family":"Landmesser","role":"aut"},{"display":"Zschäbitz, Stefanie","family":"Zschäbitz","given":"Stefanie","role":"aut"},{"role":"aut","display":"Ivanyi, Philipp","family":"Ivanyi","given":"Philipp"}],"origin":[{"dateIssuedDisp":"December 2025","dateIssuedKey":"2025"}],"note":["Online verfügbar: 6. Oktober 2025, Artikelversion: 22. November 2025","Gesehen am 27.02.2026"],"id":{"doi":["10.1016/j.clgc.2025.102449"],"eki":["1963138449"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1963138449","relHost":[{"language":["eng"],"recId":"585792658","pubHistory":["4.2005/06,3 -"],"title":[{"title":"Clinical genitourinary cancer","title_sort":"Clinical genitourinary cancer"}],"part":{"extent":"11","year":"2025","issue":"6","volume":"23","pages":"1-11","text":"23(2025), 6 vom: Dez., Artikel-ID 102449, Seite 1-11"},"id":{"eki":["585792658"],"zdb":["2466266-5"],"issn":["1938-0682"]},"note":["Gesehen am 14.04.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE) a retrospective, multicenter case seriesClinical genitourinary cancer","origin":[{"publisher":"CIG Media Group","dateIssuedKey":"2005","dateIssuedDisp":"2005-","publisherPlace":"Dallas, Tex."}],"physDesc":[{"extent":"Online-Ressource"}]}],"title":[{"title_sort":"Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE)","subtitle":"a retrospective, multicenter case series","title":"Real-world experience with Lenvatinib Plus Everolimus (LEN+EVE) in patients with pretreated advanced renal cell carcinoma (RELEVANCE)"}]} | ||
| SRT | |a EGGERSHENDREALWORLDE2025 | ||